Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Zelmac

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA Gastrointestinal Drugs Advisory Committee will meet June 26 in Gaithersburg, Md. to discuss NDA 21-200 for Novartis' Zelmac (tegaserod) for the treatment of abdominal pain and discomfort, bloating and altered bowel function in patients with irritable bowel syndrom

You may also be interested in...



Warning Letter Roundup & Recap – 22 September 2020

No device-related warning letters were released by the US FDA the week of 22 September.

Neuraxpharm Snapped Up By Private Equity In Europe’s Largest Deal

Created in 2016 by consolidating five European companies, CNS specialist Neuraxpharm is changing hands, with funds advised by global investor Permira paying an undisclosed sum to take control of a business boasting annual revenues of around €460m ($541m) and more than 115 CNS molecules at its disposal.

FDA Reveals Scale Of Perrigo Albuterol Problem

Following Perrigo’s announcement of a recall of its generic albuterol inhalers in the US, the FDA has commented on the move and has revealed that thousands of complaints have been received over the clogging problem.

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel